2026 Breakthrough Prizes Award $3M Each for Gene Therapies, ALS Link and Muon Precision at 127 ppb

The 2026 Breakthrough Prize laureates, announced April 18, each receive $3 million for gene therapies targeting inherited blindness, sickle cell disease, beta-thalassemia, plus ALS-FTD genetic links and muon measurements at 127 parts per billion precision. Co-founded by Mark Zuckerberg and Sergey Brin, the awards spotlight a gene therapy market valued at $14.4 billion in 2025, forecasted to hit $50 billion by 2030. Muon g-2 results, 30,000 times more precise than the 1965 benchmark, challenge the Standard Model and bolster U.S. annual physics R&D spending of $120 billion.